The report, released July 30, analyzed pharmacy program participants’ purchase data from April 2023 to March 2024 and provides an estimate of pharmaceutical price changes for 2025.
Vizient’s analysts predicted a 4.18% drug price inflation rate for oncology medication in 2025, more than the predicted 3.81% overall drug price inflation rate.
The oncology medications that saw the biggest share of spending were:
- Keytruda (pembrolizumab): 3.28%
- Darzalex Faspro (daratumumab-hyaluronidase-fihj): 1.36%
- Opdivo (nivolumab): 1.24%
- Imfinzi (durvalumab): 0.61%
- Tecentriq (atezolizumab): 0.54%
- Blincyto (blinatumomab): 0.53%
- Jakafi (ruxolitinib phosphate): 0.50%
- Perjeta (pertuzumab): 0.48%
- Adcetris (brentuximab vedotin): 0.45%
- Tagrisso (osimertinib mesylate): 0.45%
The top oncology medications with the greatest change in spend were:
- Kisqali (ribociclib): 190% increase
- Padcev (enfortumab vedotin-efjv): 69% increase
- Blincyto (blinatumomab): 56% increase
- Imfinzi (durvalumab): 38% increase
- Darzalex Faspro (daratumumab-hyaluronidase-fihj): 17% increase
- Keytruda (pembrolizumab): 13% increase
At the Becker's Perioperative Summit, taking place October 29–31 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
